Biotech News

Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group

Seer, Inc (SEER)Seer, IncCompany update

No Stockholder Action Required at This Time REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that it has received a highly contingent, non-binding and

Related news

Seer, Inc

Deep Proteomics Company Seer develops tools for large-scale, unbiased analysis of the proteome across research, translational medicine, and drug development. Proteograph Product Suite The Proteograph platform combines engineered nanoparticles, automated sample processing, consumables, and analytical software to capture proteins across a...

Recent company news

Stock data

Close
2.03 USD
Market cap
102.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States